Noliprel A (Indapamide, Perindopril Arginine)

Indapamide and Perindopril arginine, the active ingredients in Noliprel A, are an ACE inhibitor and a thiazide‑like diuretic presented as an oral tablet for systemic use. They are prescribed to manage hypertension in adult patients.

GNH USA supplies Noliprel A as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Noliprel A is used in the management of hypertension, a condition characterized by elevated systemic arterial pressure.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Essential hypertension: provides consistent blood pressure control when monotherapy is insufficient. - High‑risk hypertensive patients: contributes to overall risk reduction for stroke and myocardial infarction.

Noliprel A may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness or light‑headedness - Headache - Persistent dry cough - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hypotension - Acute renal impairment - Hyperkalemia - Neutropenia or agranulocytosis - Hepatic dysfunction

Before initiating Noliprel A, several safety considerations should be observed.

- Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: check serum creatinine and eGFR regularly. - Electrolyte balance: monitor potassium and sodium levels, especially in patients on other diuretics. - Hepatic impairment: use caution in patients with severe liver disease. - Diabetes management: watch for changes in blood glucose control. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Noliprel A can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Aliskiren in diabetic patients: may cause renal dysfunction. - Lithium: increased lithium levels and toxicity. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and impair renal function. - Other ACE inhibitors or ARBs: additive risk of angioedema and hypotension.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): may require dose adjustment. - Antidiabetic agents: possible enhancement of hypoglycaemic effect. - High‑dose aspirin: may affect renal perfusion. - Warfarin: potential alteration of INR values. - Corticosteroids: may increase sodium retention and counteract diuretic effect.